Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Lamotrigine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A known ✓ | Q15858 | 9/20 | 1.00 |
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 1.00 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 1.00 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 1.00 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 1.00 |
| ▸ | SCN10A known ✓ | Q9Y5Y9 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | PTPN11 | Q06124 | 7/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lamotrigine SCHEMBL722975 | 1.00 | SCN9A (1.00) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL29801510 | 1.00 | SCN9A (1.00) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL35439 | 1.00 | SCN9A (1.00) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL3976546 | 0.98 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL4142403 | 0.98 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL3167376 | 0.98 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL1401495 | 0.98 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL17372723 | 0.98 | SCN9A (0.97) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL3976541 | 0.95 | SCN9A (0.91) | SCN9ACYP2D6MAOAMAPK1ADRA1A | |
| Lamotrigine SCHEMBL6138267 | 0.91 | SCN9A (0.83) | SCN9ACYP2D6MAOAMAPK1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-3713986-B1 | COMPOSITION | REBIO TECH OY (FI) | 2026-04-01 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3931189-B1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2025-12-24 | — | — | EP | claimed |
| EP-4181891-B1 | USE OF CANNABIDIOL IN THE TREATMENT OF ABSENCE SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO BRAIN INJURY | JAZZ PHARMACEUTICALS RESEARCH UK LTD (GB) | 2025-12-17 | — | — | EP | claimed |
| EP-4210685-B1 | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | JAZZ PHARMACEUTICALS RESEARCH UK LTD (GB) | 2025-11-26 | — | — | EP | claimed |
| EP-4043016-B1 | THE 5HT AGONIST CLEMIZOLE FOR USE IN TREATING EPILEPSY DISORDERS | UNIV CALIFORNIA (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4154879-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | KOREA INST SCI & TECH (KR) | 2025-09-10 | — | — | EP | claimed |
| EP-3436000-B1 | USE OF CANNABINOIDS IN THE TREATMENT OF STURGE WEBER SYNDROME | JAZZ PHARMACEUTICALS RESEARCH UK LTD (GB) | 2025-07-16 | — | — | EP | claimed |
| US-20250222018-A1 | METHODS OF USING AVERMECTIN COMPOSITIONS FOR THE TREATMENT OF PAIN AND DOSING REGIMENS | L4 BIO LLC (US) | 2025-07-10 | — | — | US | claimed |
| EP-4057999-B1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | EVONIK OPERATIONS GMBH (DE) | 2023-12-13 | — | — | EP | claimed |
| EP-3485876-B1 | ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION | SUNSHO PHARMACEUTICAL CO LTD (JP) | 2023-11-22 | — | — | EP | claimed |
| CN-116370509-A | Application of akkermansia muciniphila in preparation of medicines for relieving and treating epilepsy | 广州知易生物科技有限公司 | 2023-07-04 | — | — | CN | claimed |
| EP-3197344-B1 | SYSTEMS AND METHODS FOR TREATING A PSYCHIATRIC DISORDER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-05-03 | — | — | EP | claimed |
| EP-3429563-B1 | DESFORMYLFLUSTRABROMINE FOR USE IN THE TREATMENT OF OBSESSIVE-COMPULSIVE AND RELATED DISORDERS | SAINT JOSEPHS UNIV (US) | 2023-04-26 | — | — | EP | claimed |
| EP-3130334-B1 | CONTROLLED-RELEASE SOLID PREPARATION WITH PARTIAL COATING | OVERSEAS PHARMACEUTICALS LTD (CN) | 2023-02-15 | — | — | EP | claimed |
| EP-3743059-B1 | AMINO ACID DERIVATIVES CONTAINING A DISULFANYL GROUP IN THE FORM OF AN NEP AND APN INHIBITOR FOR THE PREVENTION AND TREATMENT OF TRIGEMINAL NERVE PAIN | PHARMALEADS (FR) | 2023-01-11 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3454853-B1 | TREATMENT OF ALCOHOLISM AND DEPRESSION USING IBUDILAST | MEDICINOVA INC (US) | 2022-05-18 | — | — | EP | claimed |
| EP-3261640-B1 | 5HT AGONISTS FOR TREATING EPILEPSY DISORDERS | UNIV CALIFORNIA (US) | 2022-04-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250222018-A1 | METHODS OF USING AVERMECTIN COMPOSITIONS FOR THE TREATMENT OF PAIN AND DOSING REGIMENS | ACHE, LPXN, VCL | SCN9A 836/4885SCN4A 3074/4885SCN5A 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.